Table 1

Baseline characteristics

n=47
Age, years68±12
BMI (kg/m2)22.9±4.2
NYHA class ≥3, n (%)22 (46.8)
KCCQ score56.0±21.3
Male, n (%)16 (34.0)
Syncope, n (%)12 (25.5)
Hypertension, n (%)29 (61.7)
Diabetes, n (%)2 (4.3)
Dyslipidemia, n (%)27 (57.4)
Smoking, n (%)4 (8.5)
Stroke n (%)4 (8.5)
Family history of sudden death, n (%)5 (10.6)
Family history of HCM, n (%)7 (14.9)
Atrial fibrillation, n (%)8 (17.0)
COPD, n (%)2 (4.3)
Coronary artery disease, n (%)4 (8.5)
Peripheral artery disease, n (%)0 (0.0)
Malignancy, n (%)8 (17.0)
ICD/pacemaker implantation, n (%)6 (12.8)
Medication, n (%)
 Sodium channel blocker33 (70.2)
 Beta-blocker45 (95.7)
 Calcium channel blocker20 (42.6)
 Diuretics9 (19.1)
 Anticoagulation10 (21.3)
Laboratory data
 BNP (pg/mL)389.9 (156.0–802.4)
Echocardiographic variables
 LVEDD (mm)43.2±4.7
 LVESD (mm)24.5±3.2
 IVST (mm)20.9±3.0
 LAD (mm)44.6±8.5
 E/e’ (lateral)17.1±9.1
Moderate or severe MR, n (%)27 (57.0)
Resting peak LVOT PG (mm Hg)97.6±37.1
Preprocedural resting peak LVOT PG (mm Hg)74.6±47.0
  • Data are expressed as mean±SD or median (quartiles), and number (%).

  • BMI, body mass index; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; IVST, intraventricular septal thickness; KCCQ, The Kansas City Cardiomyopathy Questionnaire; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEDP, left ventricular end-diastolic pressure.; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; MR, mitral regurgitation; NYHA, New York Heart Association; PG, pressure gradient; PTSMA, percutaneous transluminal septal myocardial ablation.